X-linked recessive chondrodysplasia punctata (CDPX1) is caused by a hemizygous mutation in the arylsulfatase E (ARSE) gene located on chromosome Xp22.3. It is a rare congenital disorder of punctate calcifications in cartilages, leading to short stature and facial and limb anomalies. These clinical features are frequently observed in all types of chondrodysplasia punctata and have also been seen in other cartilage developmental disorders. Because of the phenotypical similarities, specific testing for only one gene is inefficient and time consuming. The advent of next-generation sequencing has provided an opportunity to improve diagnostic accuracy as well as save on time and cost. Here, we report on a patient diagnosed with CDPX1, who was identified via diagnostic exome sequencing to have a novel nonsense mutation in the ARSE gene, that was inherited from the mother.
INTRODUCTION
Chondrodysplasia punctata (CDP) is a clinically and genetically diverse group of rare disease that share the features of stippled epiphyses and skeletal changes. This disorder is divided into 3 types according to inheritance pattern: an autosomal recessive type, named rhizomelic chondrodysplasia punctata (RCDP), that has 3 associated genes (RCDP1 caused by the peroxisomal biogenesis factor 7 1, 2) ; an X-linked recessive type [CDPX1 caused by the arylsulfatase E (ARSE;NM_000047.2) gene] 3) ; and an X-linked dominant form (CDPX2 caused by the emopamil binding protein [EBP] gene) [2] [3] [4] . When case of CDP is suspected, genes such as PEX7, GNPAT, AGPS, ARSE, and EBP need to be analyzed. However the Sanger sequencing method can analyze only one gene at a time; therefore, failure to identify the variant of the suspected gene necessitates repeated sequencing analysis for identifying the other genes, which is very time-consuming and costly. In contrast, next-genera tion sequencing (NGS) provides a unique glimpse into the complexity of genetic disorders and has been applied to many areas of study, including medical genetics. Here, we report on a patient with CDPX1, who was confirmed via diagnostic exome sequencing (DES) (an NGS technique that uses targeted exome sequencing analysis and Sanger sequencing) to have a novel nonsense mutation in the ARSE gene and whose mother was confirmed to be an asymptomatic carrier of the mutation by Sanger sequencing.
CASE REPORT
The male infant was born at 38 weeks of gestation from the first pregnancy of a healthy 27-year-old mother and a 31-yearold father. His mother was under routine prenatal follow-up during pregnancy and showed no specific abnormalities. She did not have any chronic diseases, and there was no history of exposure to any known embryopathic agent such as warfarin.
Her family history was negative for malformations or other genetic conditions.
The infant was transferred to our neonatal intensive care unit because of desaturation and dysmorphism. Chest X-ray showed pneumomediastinum; however, desaturation was re- Table 1) .
The results revealed a C-to-T transition at the 109 th nucleotide candidate genes for a specific phenotype. The advantages of NGS its wide genome coverage and the ability to obtain from a single DNA strand. In a study on the clinical analytical sensitivity and specificity of NGS, the sensitivity was found to be 92.7% 12) . Therefore, in the cases of many other Mendelian genetic disorders that have many possible candidate genes, we recommend NGS.
However, DES does have some limitations. Sanger sequencing is more cost-effective than DES when there is a specific candidate gene involved. In addition, large rearrangements, copy 
it is a truncating variant (PVS1), 2) the variant is absent from controls (PM2), and 3) the patient's phenotype is highly specific for a disease with a single genetic etiology (PP4). To identify the origin of the variant, we collected blood from the parents and performed Sanger sequencing analysis after obtaining informed consents from both parents for genetic analysis ( Figure 2B ). As a result, we identified that it was a sequence variant of maternal origin.
The patient was discharged without any respiratory or feeding problems on hospital day 21. On last follow-up at age of 11 months, his height was still below 3%. He also had developmental delay, especially in motor and speech development. On a previous follow-up at age of 8 months, he had no optic problems such as cataract or retinopathy.
DISCUSSION
CDPX1 is one of the types of chondrodysplasia punctata that share the features of stippled epiphyses and skeletal changes.
This X-linked recessive variant is caused by a mutation in the ARSE gene located on chromosome Xp22.3 3) . Patients with mild phenotypes of CDPX1 were first reported by Sheffield et al. 6) . The clinical characteristics of CDPX1 are short stature, brachytelephalangy, dysmorphic face, nasomaxillary hypoplasia, ichthyosis, cervical myelopathy, and hearing loss. Although most affected males have minimal morbidity and skeletal findings that improve by adulthood, some have significant medical problems including respiratory compromise, cervical spine stenosis and instability, mixed conductive and sensorineural hearing loss, and intellectual disability. Stippled epiphyses on X-ray are the most important radiological feature of CPDX1 6, 7) . In approximately 25% of patients with features of CDPX1, karyotype analysis identified gene rearrangements (such as deletions, insertions, or splicing) of the short arm of the X chromosome (Xp) that includes the ARSE gene, and 60% to 75% of patients with clinical features of CDPX1 were diagnosed by identifying mutations in the ARSE gene through sequencing analysis 8) . This shows that we
